Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies.
Quick Facts
What This Study Found
Peptide-nanoparticle conjugates (like TAT-gold nanoparticles and RGD-polymer systems) overcome peptide drug limitations by improving blood-brain barrier crossing, stability, and targeted delivery for neurodegenerative diseases.
Key Numbers
Peptides <45 amino acids; examples: TAT-functionalized gold NPs, RGD-decorated polymeric systems; improved BBB crossing in preclinical models.
How They Did This
Narrative review of bionanoconjugate strategies for neurodegenerative disease therapy.
Why This Research Matters
Peptide drugs for brain diseases are limited by rapid breakdown and poor brain penetration. Nanoparticle conjugation solves both problems.
What This Study Doesn't Tell Us
Most evidence preclinical. BBB crossing in humans may differ from animal models. Manufacturing complexity. Regulatory hurdles for nanomedicines.
Trust & Context
- Original Title:
- Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies.
- Published In:
- Pharmaceutical research, 42(12), 2379-2404 (2025)
- Authors:
- Ranjitha, V R, Kumar, Anil, Kaalappa, Prashantha
- Database ID:
- RPEP-13199
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13199APA
Ranjitha, V R; Kumar, Anil; Kaalappa, Prashantha. (2025). Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies.. Pharmaceutical research, 42(12), 2379-2404. https://doi.org/10.1007/s11095-025-03941-0
MLA
Ranjitha, V R, et al. "Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies.." Pharmaceutical research, 2025. https://doi.org/10.1007/s11095-025-03941-0
RethinkPeptides
RethinkPeptides Research Database. "Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle..." RPEP-13199. Retrieved from https://rethinkpeptides.com/research/ranjitha-2025-bionanoconjugates-in-neurodegeneration-peptidenanoparticle
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.